Issues
-
Cover Image
Cover Image
The conventional dendritic cell 1 (cDC1) subset has a role in priming CD8+ T-cell responses. Whether this role is maintained in the context of central nervous system (CNS)–associated cancer is not fully known. Bowman-Kirigin et al. demonstrate in preclinical glioblastoma models that cDC1s infiltrate the brain parenchyma, where they capture tumor antigens and traffic them to the dura mater and CNS-draining lymph nodes to prime antitumor responses. In addition, the human cDC1 subset is detected in glioblastomas, meningiomas, and dura mater from patients and captures fluorescent compounds from glioblastoma, suggesting that this immune subset may also be contributing to antitumor responses in human disease. The data reveal an unappreciated role of cDC1s in priming antitumor immunity in CNS tumors. Read more in this issue on page 20. Original image from Fig. 1C. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We're Reading
Editorial
In the Spotlight
Priority Briefs
Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer
Novel immunotherapeutic strategies are needed to reduce PDAC mortality and metastatic potential. The data suggest that EUS-RFA provides an opportunity to address PDAC chemo- and immunotherapeutic resistance by stimulating the immune system and modulating the desmoplastic stroma.
Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
Despite the success of CD19-targeted CAR T-cell therapy, patients can still relapse due to CD19 antigen loss. The data clarify the relationship between genomic alterations and CD19− relapse and highlight a resistance mechanism to this targeted cancer immunotherapy.
Research Articles
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain
The authors show that cDC1 facilitate CNS antitumor immunity by capturing tumor antigens and trafficking them to the dura and CNS-draining cervical lymph nodes to prime CD8+ T-cell responses. DC antigen uptake in human glioblastoma is also demonstrated.
VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Anti-VISTA treatment overcomes adaptive resistance to immunotherapy through reprogramming myeloid suppression and relieving T-cell quiescence, highlighting the potential therapeutic impact of mAb-targeting of the VISTA immune checkpoint in cancer.
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
The clinical and biological impact of ectonucleotidases CD73 and CD39 in pancreatic adenocarcinoma (PDAC) are poorly defined. The authors reveal complementary roles for CD73 and CD39 and uncover a novel mechanism whereby CD73 promotes immune escape in PDAC.
Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer
Galectin 4 is a cancer cell–produced protein abundant in pancreatic tumors. The data show that galectin 4 blocks antitumor immunity and identify galectin 4 as a potential novel drug target for treating pancreatic cancer.
Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex
The authors show that engineering the CD3 subunit to prevent membrane lipid–mediated inhibition of CD3ε cytoplasmic domain release and subsequent TCR signaling provides a strategy to functionally engineer the TCR/CD3 complex for T cell–based cancer immunotherapy.
Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells
CaMKK2 is a target being considered for anticancer therapeutic development. The authors show CaMKK2 expression preserves NK-cell fitness in the tumor microenvironment and slows the progression of metastatic tumors—findings that should be considered when applying CaMKK2-modulating therapies.
A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors
The authors show that a novel and safe AAV-based cancer vaccine incorporating TLR9 signaling inhibition and blockade of PD-1/PD-L1 checkpoints on DCs and T cells elicits high immunogenicity for tumor-specific antigens, triggering better responses to radiotherapy.
Acknowledgment to Reviewers
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds